Completed Cystic Fibrosis trials in Denmark

Showing 1 to 25 of 30. Each trial links to its page on Pharma Observatory.

• Evaluation of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis (CF) Participants 12 to Less Than 24 Months of Age NCT05882357·Phase 3·Completed·Vertex Pharmaceuticals Incorporated·Started 2023
• A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation NCT05076149·Phase 3·Completed·Vertex Pharmaceuticals Incorporated·Started 2021
• A Study Evaluating the Long-term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis (CF) Particpants 6 Years and Older and F/MF Genotypes NCT04545515·Phase 3·Completed·Vertex Pharmaceuticals Incorporated·Started 2021
• A Study Evaluating Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis and F/MF Genotypes NCT04353817·Phase 3·Completed·Vertex Pharmaceuticals Incorporated·Started 2020
• Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy NCT04058366·Phase 3·Completed·Vertex Pharmaceuticals Incorporated·Started 2019
• A Phase 3 Study of VX-445 Combination Therapy in Cystic Fibrosis (CF) Subjects Heterozygous for F508del and a Gating or Residual Function Mutation (F/G and F/RF Genotypes) NCT04058353·Phase 3·Completed·Vertex Pharmaceuticals Incorporated·Started 2019
• A Study Evaluating the Long-term Safety of VX-445 Combination Therapy NCT04043806·Phase 3·Completed·Vertex Pharmaceuticals Incorporated·Started 2019
• A Study to Evaluate Efficacy and Safety of TEZ/IVA in Subjects Aged 6 Through 11 Years With Cystic Fibrosis NCT03559062·Phase 3·Completed·Vertex Pharmaceuticals Incorporated·Started 2018
• A Study to Evaluate the Safety and Efficacy of Long-term Treatment With TEZ/IVA in CF Participants With an F508del CFTR Mutation NCT03537651·Phase 3·Completed·Vertex Pharmaceuticals Incorporated·Started 2018
• A Phase 3 Study of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF) NCT03447249·Phase 3·Completed·Vertex Pharmaceuticals Incorporated·Started 2018
• Study Assessing the Safety, Tolerability, Pharmacokinetics, Food Effect, and Drug-Drug Interactions of PTI-801 in Healthy Volunteers, and Safety, Tolerability, and Pharmacokinetics of PTI-801 in Subjects With Cystic Fibrosis NCT03140527·Phase 1·Completed·Proteostasis Therapeutics, Inc.·Started 2017
• A Study Evaluating the Safety and Efficacy of VX-440 Combination Therapy in Subjects With Cystic Fibrosis NCT02951182·Phase 2·Completed·Vertex Pharmaceuticals Incorporated·Started 2016
• Study Assessing PTI-428 Safety, Tolerability, and Pharmacokinetics in Subjects With Cystic Fibrosis NCT02718495·Phase 1/2·Completed·Proteostasis Therapeutics, Inc.·Started 2016
• Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor NCT02544451·Phase 3·Completed·Vertex Pharmaceuticals Incorporated·Started 2015
• A Study to Evaluate the Safety and Efficacy of Long Term Treatment With VX-661 in Combination With Ivacaftor in Participants With Cystic Fibrosis Who Have an F508del-CFTR Mutation NCT02565914·Phase 3·Completed·Vertex Pharmaceuticals Incorporated·Started 2015
• A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation NCT02514473·Phase 3·Completed·Vertex Pharmaceuticals Incorporated·Started 2015
• Dose Escalation Study of QR-010 in Homozygous ΔF508 Cystic Fibrosis Patients NCT02532764·Phase 1/2·Completed·ProQR Therapeutics·Started 2015
• Saline Hypertonic in Preschoolers + CT NCT02950883·Phase 2/3·Completed·University of Washington, the Collaborative Health Studies Coordinating Center·Started 2015
• A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor NCT02347657·Phase 3·Completed·Vertex Pharmaceuticals Incorporated·Started 2015
• A Phase IIb Study of OligoG in Subjects With Cystic Fibrosis NCT02157922·Phase 2·Completed·AlgiPharma AS·Started 2014
• A Coaching Intervention to Young Adults With Cystic Fibrosis NCT02110914·Not applicable·Completed·Rigshospitalet, Denmark·Started 2014
• A Phase 3 Rollover Study of Lumacaftor in Combination With Ivacaftor in Subjects 12 Years and Older With Cystic Fibrosis NCT01931839·Phase 3·Completed·Vertex Pharmaceuticals Incorporated·Started 2013
• Pharmacokinetics of Piperacillin, Given as Continuous Infusion to Patients With Cystic Fibrosis NCT01983787·Observational·Completed·University of Aarhus·Started 2013
• A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation NCT01807949·Phase 3·Completed·Vertex Pharmaceuticals Incorporated·Started 2013
• Extension Study of Liposomal Amikacin for Inhalation in Cystic Fibrosis (CF) Patients With Chronic Pseudomonas Aeruginosa (Pa) Infection NCT01316276·Phase 3·Completed·Insmed Incorporated·Started 2012